Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Sorrento Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sorrento Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sorrento Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sorrento Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sorrento Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Sorrento Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sorrento Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sorrento Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sorrento Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sorrento Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sorrento Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Sorrento Therapeutics, Inc. Snapshot 7
Sorrento Therapeutics, Inc. Overview 7
Key Information 7
Key Facts 7
Sorrento Therapeutics, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Sorrento Therapeutics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Sorrento Therapeutics, Inc. - Pipeline Products Glance 15
Sorrento Therapeutics, Inc. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Sorrento Therapeutics, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Sorrento Therapeutics, Inc. - Drug Profiles 20
IG-002 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
paclitaxel-loaded polymeric micelle 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
resiniferatoxin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Antibody Drug Conjugate to Target CCR5 for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Biosimilar to Target CD20 for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit Ghrelin for Obesity 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit c-Myc for Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
STI-001 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
STI-A020X 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
STIA-050X 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
STIA-100X 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
STIA-1010 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
STIA-1011 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
STIA-1012 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
STIA-1014 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
STIA-1110 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
STIA-120X 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
STIA-160X 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
STIA-220X 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
STIA-230X 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
STIB-010X 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
STIB-0201 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
STIB-030X 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
STIB-120X 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
STIB-150X 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
STIC-0205 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
STIC-020X 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
STID-0168 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
STID-0602 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Clostridium difficile vaccine 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies for Clostridium difficile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies for Hepatitis C 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Sorrento Therapeutics, Inc. - Pipeline Analysis 54
Sorrento Therapeutics, Inc. - Pipeline Products by Target 54
Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration 56
Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type 57
Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action 58
Sorrento Therapeutics, Inc. - Recent Pipeline Updates 60
Sorrento Therapeutics, Inc. - Dormant Projects 63
Sorrento Therapeutics, Inc. - Discontinued Pipeline Products 64
Discontinued Pipeline Product Profiles 64
paclitaxel 64
Sorrento Therapeutics, Inc. - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Sorrento Therapeutics, Inc., Key Information 7
Sorrento Therapeutics, Inc., Key Facts 7
Sorrento Therapeutics, Inc. - Pipeline by Indication, 2014 9
Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2014 11
Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 12
Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2014 13
Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Sorrento Therapeutics, Inc. - Phase III, 2014 15
Sorrento Therapeutics, Inc. - Phase II, 2014 16
Sorrento Therapeutics, Inc. - Phase I, 2014 17
Sorrento Therapeutics, Inc. - Preclinical, 2014 18
Sorrento Therapeutics, Inc. - Discovery, 2014 19
Sorrento Therapeutics, Inc. - Pipeline by Target, 2014 55
Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2014 56
Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2014 57
Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 59
Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2014 60
Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2014 63
Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2014 64
Sorrento Therapeutics, Inc., Subsidiaries 65